Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Melanoma Patient Network Europe

Draft NICE guidance rejects GSK’s Revolade

Draft guidance from the UK's NICE has not recommended GSK's Revolade for chronic immune thrombocytopenic purpura

NICE approves RoActemra and MTX for RA

NICE has approved RoActemra plus methotrexate for use in rheumatoid patients who have failed or cannot take MabThera

NICE rejects Novartis’ Glivec for GIST

NICE has issued final guidance ruling against the use of Glivec as an adjuvant treatment following the removal of a gastrointestinal stromal tumour

NICE recommends multiple myeloma drugs

The National Institute for Health and Clinical Excellence has issued draft guidance recommending bortezomib and thalidomide for multiple myeloma

Multaq given restricted NICE approval

After rejecting the drug earlier this year, the UK's NICE has given sanofi-aventis's Multaq limited approval as a second-line treatment for atrial fibrillation

NICE criticised for Avastin rejection

The National Institute for Health and Clinical Excellence has been criticised for draft guidance recommending against Roche's cancer drug Avastin

New asthma training for nurses

A programme to help provide practice nurses with additional knowledge about the causes and management of asthma has been launched in the UK

Diabetes aspect of QiC announced

The first therapy area covered by the Quality in Care (QiC) Programme, diabetes, launches in September 2010

NICE rejects omalizumab use in children

NICE has rejected the use of omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years

NHS Reforms – the road ahead

The NHS reform agenda represents a steep learning curve for all concerned as they struggle to come to terms with the changes required to adopt and implement planned changes successfully

Monitoring of controlled drugs improves

A report released by the Care Quality Commission has said the monitoring of controlled drugs has improved, though more professional guidance is needed

Emergency drug fund for cancer patients

The UK government has announced a £50m fund allowing patients access to cancer drugs up to six months earlier than would otherwise be possible

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links